As GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound continue to surge in popularity for weight management, a new study has identified a rare but potentially fatal neurological complication tied to their use. Researchers documented 15 cases of Wernicke encephalopathy—a brain disorder caused by severe thiamine (vitamin B1) deficiency—among patients taking these medications in 2023 and 2024.
The findings, published in a peer-reviewed journal, highlight a growing concern as the drugs' use expands. Wernicke encephalopathy is a medical emergency characterized by confusion, loss of muscle coordination, and abnormal eye movements. Without prompt treatment, it can lead to permanent brain damage or death.
The study's authors note that GLP-1 drugs suppress appetite, which can drastically reduce food intake, particularly foods rich in thiamine such as pork, fish, and whole grains. This dietary reduction, combined with severe vomiting or rapid weight loss—common side effects of the medication—can precipitate the deficiency.
Most of the affected patients in the study experienced significant nausea, vomiting, or malnutrition prior to developing symptoms. The researchers emphasize that while the condition remains rare, the potential severity warrants heightened awareness among healthcare providers.
Clinical implications and monitoring
Physicians are urged to educate patients on the warning signs of thiamine deficiency, especially during the initial months of treatment when gastrointestinal side effects are most pronounced. Early recognition and immediate thiamine supplementation can reverse the condition, but delays can have devastating consequences.
The study also underscores the broader debate over the safety profile of GLP-1 drugs. While their efficacy in weight loss and glycemic control is well-documented, this new association adds to a growing list of potential adverse effects that regulators and clinicians must weigh.
Regulatory bodies are likely to review these findings, and the study's authors call for more robust pharmacovigilance. They suggest that patients on GLP-1 therapy who present with neurological symptoms should be promptly evaluated for vitamin deficiencies, including thiamine.
The findings come amid other research exploring the drugs' impact on the brain, including a recent study on semaglutide's action in the central nervous system, which may offer insights into both therapeutic and adverse effects.
As GLP-1 use continues to rise, especially among younger populations—a separate study noted a dramatic increase in prescriptions for young children—the medical community faces the challenge of balancing benefits against rare but serious risks.
For now, the study's lead researchers advise clinicians to maintain a high index of suspicion for Wernicke encephalopathy in any patient on these medications who exhibits neurological deficits, and to consider prophylactic thiamine in those with persistent vomiting or poor oral intake.
The findings also highlight the importance of nutritional monitoring during GLP-1 therapy. Patients are encouraged to maintain a balanced diet and to report any neurological symptoms to their healthcare provider immediately.
